HealthEquity posted second-quarter fiscal 2027 results on August 27, with revenue growth accelerating to 8% year over year from 7% in the first half, and adjusted EBITDA rising 11% to $167 million, a record 48% margin. The company raised its full-year guidance to $1.411 billion to $1.421 billion in revenue and $628 million to $636 million in adjusted EBITDA. New HSAs from sales jumped 24% to 202,000, total HSA assets reached $37.9 billion, and invested assets climbed 28% to $20.6 billion. CFO James Lucania acknowledged "absolutely headline price erosion" pressuring service revenue, which still grew 6% to $124.4 million, while GAAP net income of $65.6 million, or $0.78 per diluted share, trailed non-GAAP results of $103.8 million and $1.24 per share. The company returned $108.1 million to shareholders through buybacks during the quarter.
HealthEquity IncRaised fiscal 2027 guidance and reported record EBITDA margin, with strong HSA sales growth and buybacks.
